Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer Aug 19, 2016
Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine Aug 18, 2016
Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market Jun 1, 2016
Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors Feb 29, 2016
Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™ Nov 16, 2015
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements Oct 7, 2015
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia Sep 16, 2015
